$IMG
CIMG Inc. Stock $img

$img Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224017832 Filed on May 06, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2022 Q4
Revenue	$366.9K	$1.354M	$1.136M
YoY Change	-43.43%	19.15%	11.49%
Cost Of Revenue	$513.1K	$1.179M	$1.061M
YoY Change	-13.97%	11.11%	5.67%
Gross Profit	-$146.2K	$175.3K	$75.53K
YoY Change	-380.35%	132.06%	391.42%
Gross Profit Margin	-39.85%	12.95%	6.65%
Selling, General & Admin	$54.24K	$43.76K	$91.12K
YoY Change	200.67%	-51.98%
% of Gross Profit		24.97%	120.64%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$33.92K	$39.98K	$73.81K
YoY Change	-50.62%	-45.83%	101.05%
% of Gross Profit		22.81%	97.71%
Operating Expenses	$1.335M	$2.318M	$2.277M
YoY Change	-35.42%	1.8%	-19.0%
Operating Profit	-$1.482M	-$2.143M	-$2.202M
YoY Change	-26.5%	-2.67%	-21.25%
Interest Expense	-$1.780K	-$2.560K	$3.520K
YoY Change	-214.84%	-172.73%	-194.62%
% of Operating Profit
Other Income/Expense, Net	$290.9K	$50.10K	$14.95K
YoY Change	-2713.93%	235.12%	-420.13%
Pretax Income	-$1.192M	-$2.149M	-$2.183M
YoY Change	-41.12%	-1.58%	-22.14%
Income Tax
% Of Pretax Income
Net Earnings	-$1.440M	-$2.149M	-$2.183M
YoY Change	-28.89%	-1.58%	-22.15%
Net Earnings / Revenue	-392.54%	-158.69%	-192.12%
Basic Earnings Per Share	-$0.92	-$1.84	-$3.23
Diluted Earnings Per Share	-$0.92	-$1.84	-$3.23
COMMON SHARES
Basic Shares Outstanding	1.298M shares	1.168M shares	23.67M shares
Diluted Shares Outstanding	1.561M shares	1.168M shares	676.4K shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$374.5K	$432.2K	$6.492M
YoY Change	-88.59%	-93.34%	-40.81%
Cash & Equivalents	$374.5K	$432.2K	$6.492M
Short-Term Investments
Other Short-Term Assets	$240.9K	$389.6K	$376.3K
YoY Change	-14.96%	3.55%	-44.09%
Inventory	$937.2K	$1.254M	$1.090M
Prepaid Expenses
Receivables	$371.8K	$1.130M	$653.9K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.924M	$3.205M	$8.612M
YoY Change	-61.97%	-62.78%	-32.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$375.5K	$584.1K	$475.3K
YoY Change	4.3%	22.9%	-59.81%
Goodwill
YoY Change
Intangibles	$87.50K	$102.5K	$132.5K
YoY Change	-25.53%	-22.64%
Long-Term Investments	$158.5K	$160.2K	$167.8K
YoY Change	-3.54%	-4.53%	-3.71%
Other Assets	$2.353K	$80.37K	$91.98K
YoY Change	-97.19%	-12.62%	15.57%
Total Long-Term Assets	$824.1K	$1.368M	$1.437M
YoY Change	-31.12%	-4.81%	0.05%
TOTAL ASSETS
Total Short-Term Assets	$1.924M	$3.205M	$8.612M
Total Long-Term Assets	$824.1K	$1.368M	$1.437M
Total Assets	$2.748M	$4.573M	$10.05M
YoY Change	-56.07%	-54.49%	-29.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.378M	$2.534M	$462.7K
YoY Change	106.4%	447.8%	-32.12%
Accrued Expenses	$100.7K	$345.1K	$624.3K
YoY Change	-66.15%	-44.73%	86.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$222.0K	$20.98K	$36.73K
YoY Change	527.59%	-42.88%	-39.13%
Total Short-Term Liabilities	$2.726M	$3.236M	$1.830M
YoY Change	45.08%	76.86%	22.1%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$21.24K
YoY Change	-100.0%	-100.0%	-61.07%
Other Long-Term Liabilities	$215.9K	$262.9K	$77.34K
YoY Change	357.23%	239.92%	-81.43%
Total Long-Term Liabilities	$215.9K	$350.0K	$283.9K
YoY Change	0.79%	23.28%	-39.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.726M	$3.236M	$1.830M
Total Long-Term Liabilities	$215.9K	$350.0K	$283.9K
Total Liabilities	$2.942M	$3.586M	$2.114M
YoY Change	40.55%	69.66%	7.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$78.61M	-$75.52M	-$66.81M
YoY Change	11.04%	13.05%
Common Stock	$78.27M	$76.34M	$74.54M
YoY Change	4.6%	2.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$193.6K	$986.4K	$7.935M
YoY Change
Total Liabilities & Shareholders Equity	$2.748M	$4.573M	$10.05M
YoY Change	-56.07%	-54.49%	-29.51%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2022 Q4
OPERATING ACTIVITIES
Net Income	-$1.440M	-$2.149M	-$2.183M
YoY Change	-28.89%	-1.58%	-22.15%
Depreciation, Depletion And Amortization	$33.92K	$39.98K	$73.81K
YoY Change	-50.62%	-45.83%	101.05%
Cash From Operating Activities	-$961.7K	-$2.336M	-$1.913M
YoY Change	-30.06%	22.09%	21.12%
INVESTING ACTIVITIES
Capital Expenditures	$4.100K	$307.0K	$16.51K
YoY Change	-77.68%	1759.3%	-648.64%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$4.100K	-$307.0K	-$16.51K
YoY Change	-77.68%	1759.3%	448.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$1.099M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.747M	$1.660M	-$8.857K
YoY Change	-28736.89%	-18840.6%	-100.52%
NET CHANGE
Cash From Operating Activities	-961.7K	-$2.336M	-$1.913M
Cash From Investing Activities	-4.100K	-$307.0K	-$16.51K
Cash From Financing Activities	1.747M	$1.660M	-$8.857K
Net Change In Cash	781.0K	-$940.9K	-$1.823M
YoY Change	-155.81%	-48.39%	-1639.11%
FREE CASH FLOW
Cash From Operating Activities	-$961.7K	-$2.336M	-$1.913M
Capital Expenditures	$4.100K	$307.0K	$16.51K
Free Cash Flow	-$965.8K	-$2.643M	-$1.930M
YoY Change	-30.68%	36.96%	22.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2023Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2022Q4	NUZE	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2023Q4	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
CY2023Q4	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2022Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022Q4	NUZE	Proceeds From Equipment Finance ProceedsFromEquipmentFinance		usd
CY2022Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022Q4	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022Q4	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q4	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths		usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross		usd
CY2023Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q3	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Non Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueOutstanding		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023Q4	NUZE	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2023Q4	NUZE	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q4	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Non Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueOutstanding		usd
CY2023Q4	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Non Options Exercisable Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested		usd
CY2023Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q4	dei	Entity File Number EntityFileNumber	001-39338
CY2023Q4	dei	Entity Registrant Name EntityRegistrantName	NUZEE, INC.
CY2023Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	38-3849791
CY2023Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	2865 Scott St. Suite 107
CY2023Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Vista
CY2023Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92081
CY2023Q4	dei	City Area Code CityAreaCode	(760)
CY2023Q4	dei	Local Phone Number LocalPhoneNumber	295-2408
CY2023Q4	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value
CY2023Q4	dei	Trading Symbol TradingSymbol	NUZE
CY2023Q4	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q4	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1298414	shares
CY2023Q4	us-gaap	Cash Cash	432154	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1129500	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1253646	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	389614	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3204914	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	584119	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	440711	usd
CY2023Q4	us-gaap	Investments Investments	160208	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	102500	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	80374	usd
CY2023Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	783793	usd
CY2023Q4	us-gaap	Assets Assets	4572826	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2534408	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	2732	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	345045	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	18251	usd
CY2023Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	305432	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	30478	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3236346	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34831	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	315210	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	47937	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	350041	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	210238	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3586387	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2766641	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1284194	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1284194	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	13	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	8	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	76344123	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	74925843	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75520598	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73371987	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	162901	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	120493	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	986439	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1674357	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4572826	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4440998	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1353986	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1136348	usd
CY2022Q4	us-gaap	Cost Of Revenue CostOfRevenue	1060816	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	2318234	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2142955	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2201668	usd
CY2023Q4	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2051	usd
CY2022Q4	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1823	usd
CY2023Q4	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	47011	usd
CY2022Q4	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	50737	usd
CY2023Q4	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	50100	usd
CY2022Q4	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	35790	usd
CY2023Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-516	usd
CY2022Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	5338	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-2148611	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2183206	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.84
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.84
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.23
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.23
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1168221	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1168221	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	676422	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	676422	shares
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-2148611	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2183206	usd
CY2023Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	42408	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	115583	usd
CY2023Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	42408	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	115583	usd
CY2023Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2106203	usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2067623	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1674357	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1277118	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	11505	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	129662	usd
CY2023Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	42408	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-2148611	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	986439	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9742799	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9742799	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	197108	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	62839	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	115583	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2183206	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7935123	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7935123	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2183206	usd
CY2023Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	39980	usd
CY2022Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	73805	usd
CY2023Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	68372	usd
CY2022Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	73103	usd
CY2023Q4	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	11505	usd
CY2022Q4	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	197108	usd
CY2022Q4	us-gaap	Restricted Stock Expense RestrictedStockExpense	62839	usd
CY2022Q4	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	65608	usd
CY2023Q4	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2051	usd
CY2022Q4	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1823	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	542622	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	374253	usd
CY2023Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	255576	usd
CY2022Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	141906	usd
CY2023Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	88033	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-171509	usd
CY2023Q4	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	697	usd
CY2022Q4	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	14017	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	702295	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	348947	usd
CY2023Q4	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-74363	usd
CY2022Q4	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-21684	usd
CY2023Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-104378	usd
CY2022Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-78046	usd
CY2023Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-67088	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-105931	usd
CY2023Q4	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	120999	usd
CY2022Q4	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	10855	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2336166	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1913446	usd
CY2023Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	307044	usd
CY2022Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16514	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-307044	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16514	usd
CY2023Q4	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	2021	usd
CY2022Q4	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1968	usd
CY2023Q4	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	7797	usd
CY2022Q4	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	6889	usd
CY2023Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	129662	usd
CY2023Q4	NUZE	Proceeds From Equipment Finance ProceedsFromEquipmentFinance	262893	usd
CY2023Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1099254	usd
CY2023Q4	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	177864	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1659855	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8857	usd
CY2023Q4	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	42408	usd
CY2022Q4	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	115583	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-940947	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1823234	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1373101	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8315053	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	432154	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6491819	usd
CY2023Q4	us-gaap	Interest Paid Net InterestPaidNet	782	usd
CY2022Q4	us-gaap	Interest Paid Net InterestPaidNet	1474	usd
CY2023Q4	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1288	usd
CY2023Q4	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	105825	usd
CY2022Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	ratio from 1-for-10 to 1-for-50
CY2022Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-35
CY2023Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1284194	shares
CY2022Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	262030	shares
CY2023Q4	us-gaap	Cash Cash	432154	usd
CY2023Q4	NUZE	Working Capital WorkingCapital	85187	usd
CY2023Q4	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zXlCqz2Mhku6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_866_zXDo7dtj6rl">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In preparing these consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_z94gvb4NFiy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_86B_zSkipz34KAl5">Concentration of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company places its cash with high quality banking institutions. From time to time, the Company may or may not maintain cash balances at certain institutions in excess of the Federal Deposit Insurance Corporation limit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	58636	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	58636	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	379876	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	345045	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34831	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	403258	usd
CY2023Q4	NUZE	Addition For Right Of Use Of Assets AdditionForRightOfUseOfAssets	105825	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	68372	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	440711	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	378429	usd
CY2023Q4	NUZE	Addition For Lease Liability AdditionForLeaseLiability	105825	usd
CY2023Q4	NUZE	Operating Lease Lease Liability Amortization Expense OperatingLeaseLeaseLiabilityAmortizationExpense	104378	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	379876	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	345045	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34831	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	379876	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	227943	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	88430	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	316373	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	63503	usd
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y3M18D
CY2023Q4	us-gaap	Lessee Finance Lease Discount Rate LesseeFinanceLeaseDiscountRate	0.1275	pure
CY2023Q4	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	782	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	19315	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	19315	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1064	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	18251	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	18251	usd
CY2023Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	80761	usd
CY2023Q4	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	782	usd
CY2023Q4	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	7797	usd
CY2023Q4	us-gaap	Sublease Income SubleaseIncome	46832	usd
CY2023Q4	NUZE	Sub Lease Liability Payments Due Next Twelve Months SubLeaseLiabilityPaymentsDueNextTwelveMonths	64918	usd
CY2023Q4	NUZE	Minimum Lease Payments To Be Received Sublease MinimumLeasePaymentsToBeReceivedSublease	64918	usd
CY2023Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	42408	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	115583	usd
CY2023Q4	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2051	usd
CY2022Q4	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1823	usd
CY2023Q4	us-gaap	Other Expenses OtherExpenses	50100	usd
CY2022Q4	us-gaap	Other Expenses OtherExpenses	35790	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	389614	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	418200	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	389614	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	418200	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1253646	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	998070	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1225534	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	982626	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	28112	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15444	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1253646	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	998070	usd
CY2023Q4	us-gaap	Depreciation Depreciation	32480	usd
CY2022Q4	us-gaap	Depreciation Depreciation	66305	usd
CY2023Q4	NUZE	Property And Equipment Description PropertyAndEquipmentDescription	Expenditures associated with upgrades and enhancements that improve, add functionality, or otherwise extend the life of property and equipment that exceed $1,000 are capitalized.
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1136348	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	584119	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	309555	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2253784	usd
CY2023Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1895859	usd
CY2023Q4	us-gaap	Public Utilities Property Plant And Equipment Vehicles PublicUtilitiesPropertyPlantAndEquipmentVehicles	78378	usd
CY2023Q3	us-gaap	Public Utilities Property Plant And Equipment Vehicles PublicUtilitiesPropertyPlantAndEquipmentVehicles	73980	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1748043	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1660284	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	584119	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	309555	usd
CY2023Q4	NUZE	Purchase Of Deposit Equipment PurchaseOfDepositEquipment	0	usd
CY2023	NUZE	Purchase Of Deposit Equipment PurchaseOfDepositEquipment	0	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	262893	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1353986	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10D
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	102500	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	30000	usd
CY2023Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7500	usd
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7500	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	22500	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	30000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	30000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	20000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	102500	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	96458	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	150.39
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M2D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	7993	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	107.93
CY2023Q4	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Forfeited And Expired Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedAndExpiredWeightedAverageRemainingContractualTerm2	P0Y2M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	88465	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	154.23
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M29D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	65782	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	179.28
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	24029	shares
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	80.73
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	1334	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	48.35
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	12	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	587.65
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	22683	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	82.37
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	152398	shares
CY2023Q3	NUZE	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1	158.24
CY2023Q4	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm	P2Y7M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	152398	shares
CY2023Q4	NUZE	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1	158.24
CY2023Q4	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm	P2Y7M24D
CY2023Q4	NUZE	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	152398	shares
CY2023Q4	NUZE	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercisable In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisableInPeriodWeightedAverageExercisePrice	158.24
CY2023Q4	NUZE	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTermExercisable	P2Y7M24D
CY2023Q4	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_802_eus-gaap--LossContingencyDisclosures_zzXooXL0nMgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. <span id="xdx_82C_zspjTEXg8P5b">CONTINGENCY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Steeped, Inc. Litigation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 27, 2023, Steeped, Inc. d/b/a Steeped Coffee (“Steeped”) filed a complaint against the Company in the Superior Court of California, Santa Cruz County (Case No. 23CV00234) (the “Steeped Litigation”). The Steeped Litigation relates to Steeped’s claim that the Company breached a 2021 settlement agreement that resolved Steeped’s 2019 trademark infringement case against the Company. The earlier case involved Steeped’s purported trademark protection for “steeped coffee” and related phrases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steeped’s operative complaint in the pending Steeped Litigation alleges breach of contract, intentional interference with contractual relations, intentional interference with prospective economic advantage, and fraud in the inducement of contract. Plaintiff seeks a trial by jury and relief in the form of a permanent injunction for use of “Steep Coffee” or any confusingly similar variant of “STEEPED COFFEE”; the impoundment and destruction of allegedly violating packaging materials and/or finished goods; a final judgment for all profits derived from the Company’s allegedly unlawful conduct, actual damages, damages to the Plaintiff’s reputation and goodwill among its customers and partners; and reasonable attorneys’ fees and costs. NuZee answered Steeped’s complaint with a general denial and asserted twenty-five affirmative defenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 16, 2024, a mediation hearing was held. After the close of business, the mediator suggested a settlement amount of $<span id="xdx_90E_eus-gaap--LossContingencyDamagesAwardedValue_c20240116__20240116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgjf9OZ1OW1g" title="Settlement amount">500,000</span> which both parties agreed to accept. While the amount was agreed to, a payment schedule was not agreed on. Negotiations between the parties to establish an acceptable payment schedule are ongoing. The settlement amount is accrued in the financial statements as of December 31, 2023 and is included in current liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Curtin Litigation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 6, 2023, a former employee of the Company, Rosaline Curtin (“Ms. Curtin”), filed a complaint against the Company and another former employee of the Company, Jose Ramirez (“Mr. Ramirez”), in the Superior Court of California, County of San Diego (Case No. 37-2023-00000841-CU-WT-NC) (the “Curtin Complaint”). The Curtin Complaint alleges that Ms. Curtin was subject to harassment by her supervisor, Mr. Ramirez, and gender discrimination throughout her employment, that she reported this discrimination and harassment to the Company, and that the Company retaliated against her and wrongfully terminated her for whistleblowing and failed to prevent discrimination, harassment, and retaliation. The Curtin Complaint seeks compensatory damages, including loss of past, present and future earnings, and benefits, as well as punitive damages, penalties, attorney’s fees and costs and interest. The Company has responded to the complaint on behalf of the Company and Mr. Ramirez and prevailed on December 22, 2023, prevailed on its motion to compel. Arbitration proceedings have been initiated, and the parties have agreed on an arbitrator. A date for the arbitration hearing has not yet been scheduled. We believe the allegations set forth in the Curtin Complaint are without merit and intend to defend vigorously against the allegations. However, the Company is not able to predict the outcome, and there is no assurance that the Company will be successful in its defense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. The results of any future litigation cannot be predicted with certainty, and, regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Matters that are probable of unfavorable outcomes to us and which can be reasonably estimated are accrued. Such accruals are based on information known about the matters, our estimates of the outcomes of such matters and our experience in contesting, litigating and settling similar matters.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1674357	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-017832-index-headers.html	Edgar Link	pending
0001493152-24-017832-index.html	Edgar Link	pending
0001493152-24-017832.txt	Edgar Link	pending
0001493152-24-017832-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nuze-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nuze-20231231_lab.xml	Edgar Link	unprocessable
nuze-20231231_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
nuze-20231231_cal.xml	Edgar Link	unprocessable
nuze-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMG
CIMG Inc. Stock $img

2024 Q2 Form 10-Q Financial Statement

#000149315224017832 Filed on May 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMG CIMG Inc. Stock $img

2024 Q2 Form 10-Q Financial Statement

#000149315224017832 Filed on May 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMG
CIMG Inc. Stock $img